After nearly a quarter century without a new post-traumatic stress disorder drug, regulators are weighing a few late-stage options while most patients still rely on two aging antidepressants.
Story Snapshot
- Only two drugs remain approved for post-traumatic stress disorder after two decades without a new approval.
- Drug makers advanced a filing to pair brexpiprazole with sertraline for post-traumatic stress disorder.
- The Food and Drug Administration rejected MDMA-assisted therapy in 2024 after an advisory vote against it.
- Federal updates show active studies, not near-term availability, for newer compounds.
The long drought in approved post-traumatic stress disorder medicines
Food and Drug Administration records show only sertraline and paroxetine are approved for post-traumatic stress disorder. Sertraline won approval in 1999, and paroxetine followed in 2001. Agency briefings in 2025 repeated that no other post-traumatic stress disorder drugs have been approved since then. Veterans Affairs analyses have called this a stalled field for years, underscoring how little progress patients have seen in daily care despite many trials and headlines.
For families, the stall has real costs. Millions live with flashbacks, nightmares, and anxiety. Doctors often start with the same selective serotonin reuptake inhibitors used decades ago. Some patients improve. Many stop early because of side effects or modest relief. That gap feeds search for faster and more durable options. Reviewers now track a small set of late-stage candidates, but they remain under study or review rather than ready for pharmacy shelves today.
What is actually moving in the pipeline
Otsuka and Lundbeck reported that the Food and Drug Administration accepted a supplemental filing for brexpiprazole used with sertraline to treat post-traumatic stress disorder. The companies said approval would make it the first new pharmacologic option in more than twenty years. The filing signals that larger, controlled trials were run and packaged, but the agency still must decide on safety and benefit before any label change occurs.
A recent review table lists several late-stage ideas, such as atypical antipsychotics, ketamine approaches, and plant-derived compounds. Some aim to treat core symptoms. Others target related problems like sleep disturbance or anxiety. The list shows active work, but it mixes different goals and endpoints. That makes it hard to compare programs head to head or to predict which ones can hit the Food and Drug Administration’s bar for approval.
Setbacks for psychedelics and the government’s current stance
The Department of Veterans Affairs summarized the 2024 advisory meeting where outside experts advised against approving MDMA-assisted therapy for post-traumatic stress disorder. The Food and Drug Administration later issued a formal denial, asking for more and stronger evidence. The decision slowed a high-profile path that many thought could break the drought, and it reminded sponsors that durable, well-controlled data are still required.
The Food and Drug Administration in 2026 announced steps to speed research on serious mental illness. The agency allowed a study of methylone in post-traumatic stress disorder to proceed and created priority vouchers tied to that work. The agency stressed that study permission does not mean a drug is safe, effective, or approved. This shows federal interest in faster development while keeping the usual safety checks in place.
Why both sides of the aisle care about this gap
Veterans, first responders, abuse survivors, and crime victims carry the heaviest load when treatments fall short. Conservatives see a system that spends big but delivers slow results. Liberals see unequal access and long waits for care. Both sides see a government that struggles to clear red tape and push clear answers to the clinic. The long break in approvals, the mixed trial record, and the recent psychedelic setback all feed that shared frustration.
After 25 Years Without a New PTSD Drug, Here's What's in the Pipeline https://t.co/8r2elCv5qL
— Boone Cutler 🦬🇺🇸 🦅 (@boonecutler) August 31, 2026
What to watch next is simple and specific. First, the brexpiprazole plus sertraline decision will test whether add-on strategies can clear the bar for a label. Second, sponsors must release full data packages so doctors can judge real-world value. Third, federal reviewers have signaled openness to new targets, but they will still demand strong, durable effects. Until then, sertraline and paroxetine remain the only approved options in the United States.
Sources:
military.com, research.va.gov, ptsd.va.gov, pmc.ncbi.nlm.nih.gov, otsuka-us.com, fda.gov
